Cuál es el precio por Vertex Pharmaceuticals Incorporated (VRTX)

Precio por Vertex Pharmaceuticals Incorporated (VRTX) es de$451.59

Cuál es la capitalización de mercado por Vertex Pharmaceuticals Incorporated (VRTX)

Capitalización de mercado por Vertex Pharmaceuticals Incorporated (VRTX) es $114.70B

Ganancias de Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Año	Ganancias	Cambiar
2026 (TTM)	$4.64B	0.00%
2025	$4.64B	1,768.49%
2024	$248.50M	-94.33%
2023	$4.38B	3.48%
2022	$4.23B	55.01%
2021	$2.73B	-12.40%
2020	$3.12B	123.45%
2019	$1.39B	132.39%
2018	$600.24M	-3,925.87%
2017	$-15.69M	-76.71%
2016	$-67.37M	-87.96%
2015	$-559.58M	-23.85%
2014	$-734.88M	-24.71%
2013	$-976.12M	7,783.99%
2012	$-12.38M	-120.48%
2011	$60.45M	-108.01%
2010	$-754.63M	17.51%
2009	$-642.18M	38.35%
2008	$-464.18M	8.73%
2007	$-426.91M	106.35%
2006	$-206.89M	19.32%
2005	$-173.39M	9.39%
2004	$-158.51M	-54.37%
2003	$-347.35M	190.28%
2002	$-119.66M	1.50%
2001	$-117.89M	119.92%
2000	$-53.61M	0.00%

Año

Ganancias

Cambiar

2026 (TTM)

$4.64B

0.00%

2025

$4.64B

1,768.49%

2024

$248.50M

-94.33%

2023

$4.38B

3.48%

2022

$4.23B

55.01%

2021

$2.73B

-12.40%

2020

$3.12B

123.45%

2019

$1.39B

132.39%

2018

$600.24M

-3,925.87%

2017

$-15.69M

-76.71%

2016

$-67.37M

-87.96%

2015

$-559.58M

-23.85%

2014

$-734.88M

-24.71%

2013

$-976.12M

7,783.99%

2012

$-12.38M

-120.48%

2011

$60.45M

-108.01%

2010

$-754.63M

17.51%

2009

$-642.18M

38.35%

2008

$-464.18M

8.73%

2007

$-426.91M

106.35%

2006

$-206.89M

19.32%

2005

$-173.39M

9.39%

2004

$-158.51M

-54.37%

2003

$-347.35M

190.28%

2002

$-119.66M

1.50%

2001

$-117.89M

119.92%

2000

$-53.61M

0.00%

Empresa	Ganancias	Diferencia de ganancias	País
Novo Nordisk A/S NVO.US	$20.46B	340.58%	DK
Regeneron Pharmaceuticals, Inc. REGN.US	$5.23B	12.65%	US
UCB SA UCB.BR	$2.14B	-53.96%	BE
CSL Limited CSL.AX	$1.61B	-65.23%	AU
Argenx SE ARGX.US	$1.45B	-68.75%	NL

Empresa

Ganancias

Diferencia de ganancias

País